Search our Database of Scientific Publications and Authors

I’m looking for a

    8320 results match your criteria Breast cancer research and treatment[Journal]

    1 OF 167

    Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Breast Cancer Res Treat 2018 Jan 22. Epub 2018 Jan 22.
    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.
    Purpose: Cell-cycle-checkpoint kinase 2 (CHEK2) is an important moderate-penetrance breast cancer predisposition gene; however, recurrent CHEK2 mutations found in Caucasian women are very rare in Chinese population. We investigated the mutation spectrum and clinical relevance of CHEK2 germline mutations in Chinese breast cancer patients.

    Methods: The entire coding regions and splicing sites of CHEK2 were screened in 7657 Chinese BRCA1/2-negative breast cancer patients, using 62-gene panel-based sequencing. Read More

    Management and outcomes of women diagnosed with primary breast lymphoma: a multi-institution experience.
    Breast Cancer Res Treat 2018 Jan 22. Epub 2018 Jan 22.
    Harvard University, Boston, MA, USA.
    Purpose: Primary breast lymphoma (PBL) comprises < 1% of breast malignancies, leading to a paucity of data to guide management. We evaluated PBL recurrence patterns across two academic hospitals in the era of modern systemic-therapy and radiotherapy.

    Methods: Patients diagnosed with PBL between October 1994 and June 2016 were identified. Read More

    Surveillance for cancer recurrence in long-term young breast cancer survivors randomly selected from a statewide cancer registry.
    Breast Cancer Res Treat 2018 Jan 20. Epub 2018 Jan 20.
    Nursing Science, Faculty of Medicine, University of Basel, Bernoullistrasse 28, 4056, Basel, Switzerland.
    Purpose: This study examined clinical breast exam (CBE) and mammography surveillance in long-term young breast cancer survivors (YBCS) and identified barriers and facilitators to cancer surveillance practices.

    Methods: Data collected with a self-administered survey from a statewide, randomly selected sample of YBCS diagnosed with invasive breast cancer or ductal carcinoma in situ younger than 45 years old, stratified by race (Black vs. White/Other). Read More

    Is invasion a necessary step for metastases in breast cancer?
    Breast Cancer Res Treat 2018 Jan 20. Epub 2018 Jan 20.
    Women's College Research Institute, Women's College Hospital, 76 Grenville Street, Toronto, M5S 1B2, Canada.
    Purpose: To review the empirical evidence to support the conventional (sequential) model of breast cancer progression, which is based on the paradigm that cancer passes through several stages, including an in situ stage prior to an invasive stage, and thereafter (in some cases) disseminates to the lymph nodes and distant organs.

    Methods: We review the cancer literature of the last 50 years which relates to the prevention of invasive breast cancer (through radiotherapy or surgery) and reductions in the mortality for breast cancer.

    Results: For both invasive cancers and DCIS, the literature indicates that prevention of in-breast invasive recurrences does not prevent death from breast cancer. Read More

    Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG).
    Breast Cancer Res Treat 2018 Jan 19. Epub 2018 Jan 19.
    University of Miami, Deerfield Beach, FL, USA.
    Purpose: Management of breast cancer is a rapidly evolving field, and, although evidence-based guidelines are available for clinicians to provide direction on critical issues in patient care, clinicians often left to address these issues in the context of community practice situations with their patients. These include the patient's comorbid conditions, actual versus perceived benefit of treatments, patient's compliance as well as financial/reimbursement issues, and long-term tolerability of therapy.

    Methods: A meeting of global oncology experts was convened in January 2017 with the belief that there is a gap in clinical practice guidance on several fundamental issues in breast cancer care, particularly in the community setting, where oncologists may encounter multiple tumor types. Read More

    The PPARγ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ.
    Breast Cancer Res Treat 2018 Jan 19. Epub 2018 Jan 19.
    Department of Oncology, Georgetown University, Washington, DC, USA.
    Purpose: Ductal carcinoma in situ (DCIS) is a pre-invasive lesion of the breast considered a precursor of invasive ductal carcinoma. This study aimed to determine whether activated PPARγ acts as a tumor suppressor in human DCIS progression.

    Methods: We utilized the high-affinity PPARγ agonist, efatutazone, to activate endogenous PPARγ in a well-defined model for the progression of basal (triple negative) DCIS, MCFDCIS cells, cultured under 2D and 3D conditions. Read More

    Living with chronic pain: perceptions of breast cancer survivors.
    Breast Cancer Res Treat 2018 Jan 19. Epub 2018 Jan 19.
    Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.
    Purpose: Breast cancer treatments may lead to chronic pain. For some breast cancer survivors (BCS), this experience can develop into the perception of living with chronic pain. The majority of BCS are postmenopausal and have hormone receptor-positive (HR+) breast cancer requiring aromatase inhibitors (AIs). Read More

    Patient-reported outcomes of catheter-based accelerated partial breast brachytherapy and whole breast irradiation, a single institution experience.
    Breast Cancer Res Treat 2018 Jan 18. Epub 2018 Jan 18.
    Department of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA.
    Purpose: Accelerated partial breast irradiation (APBI) and whole breast irradiation (WBI) are treatment options for early-stage breast cancer. The purpose of this study was to compare patient-reported-outcomes (PRO) between patients receiving multi-channel intra-cavitary brachytherapy APBI or WBI.

    Methods: Between 2012 and 2015, 131 patients with ductal carcinoma in situ (DCIS) or early stage invasive breast cancer were treated with adjuvant APBI (64) or WBI (67) and participated in a PRO questionnaire. Read More

    Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial.
    Breast Cancer Res Treat 2018 Jan 18. Epub 2018 Jan 18.
    Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.
    Background: Advanced therapeutic strategies are often accompanied by significant adverse effects, which warrant equally progressive countermeasures. Physical exercise has proven an effective intervention to improve physical function and reduce fatigue in patients undergoing chemotherapy. Effects of high-intensity interval training (HIIT) in this population are not well established although HIIT has proven effective in other clinical populations. Read More

    Impact of an embedded genetic counselor on breast cancer treatment.
    Breast Cancer Res Treat 2018 Jan 18. Epub 2018 Jan 18.
    Division of Breast Services, Department of General Surgery, Cleveland Clinic, 9500 Euclid Ave./A80, Cleveland, OH, 44195, USA.
    Background: We predicted that embedding a genetic counselor within our breast practice would improve identification of high-risk individuals, timeliness of care, and appropriateness of surgical decision making. The aim of this study is to compare cancer care between 2012 and 2014, prior to embedding a genetic counselor in the breast center and following the intervention, respectively.

    Methods: A retrospective review of patients diagnosed with breast cancer in 2012 (n = 471) and 2014 (n = 440) was performed to assess patterns of medical genetics referral, compliance with referral, genetic testing findings, and impact on treatment. Read More

    Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.
    Breast Cancer Res Treat 2018 Jan 18. Epub 2018 Jan 18.
    Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, PO Box 30001, 9700 RB, Groningen, The Netherlands.
    Purpose: The Ki67 proliferation index is a prognostic and predictive marker in breast cancer. Manual scoring is prone to inter- and intra-observer variability. The aims of this study were to clinically validate digital image analysis (DIA) of Ki67 using virtual dual staining (VDS) on whole tissue sections and to assess inter-platform agreement between two independent DIA platforms. Read More

    Assessment of potential risk factors for breast cancer in a population in Southern Brazil.
    Breast Cancer Res Treat 2018 Jan 17. Epub 2018 Jan 17.
    Hospital Moinhos de Vento, Porto Alegre, Brazil.
    Purpose: The aim of this study is to assess potential risk factors for breast cancer in a population in Southern Brazil and build a multivariate logistic model using these factors for breast cancer risk prediction.

    Methods: A total of 4242 women between 40 and 69 years of age without a history of breast cancer were selected at primary healthcare facilities in Porto Alegre and submitted to mammographic screening. They were evaluated for potential risk factors. Read More

    Associations of coffee consumption and caffeine intake with mammographic breast density.
    Breast Cancer Res Treat 2018 Jan 17. Epub 2018 Jan 17.
    Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
    Purpose: Previous studies suggest that coffee and caffeine intake may be associated with reduced breast cancer risk. We investigated the association of coffee and caffeine intake with mammographic breast density by woman's menopausal status and, in postmenopausal women, by hormone therapy (HT).

    Methods: This study included 4130 cancer-free women within the Nurses' Health Study and Nurses' Health Study II cohorts. Read More

    Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis.
    Breast Cancer Res Treat 2018 Jan 16. Epub 2018 Jan 16.
    Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Avda. Marqués de los Velez, s/n, 30008, Murcia, Spain.
    Purpose: Therapeutic exploitation of angiogenesis in breast cancer has been limited by the lack of reliable biomarkers. Circulating small-sized endothelial microparticles (sEMP) are likely to play a significant role as messengers of angiogenesis. Higher levels of EMP have been observed in cancer patients, but their prognostic value in breast cancer is unknown. Read More

    Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
    Breast Cancer Res Treat 2018 Jan 16. Epub 2018 Jan 16.
    Division of Molecular Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
    Purpose: Non-invasive blood-based molecular markers have been investigated for cancer diagnosis and prognosis. Circulating free or cell-free DNA (cfDNA) variables have been shown to be putative markers in breast cancer prognosis.

    Methods: Here, we investigated the potential prognostic ability of cfDNA concentration and cfDNA integrity (cfDI) in a study cohort of 268 patients by quantitative PCR. Read More

    GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
    Breast Cancer Res Treat 2018 Jan 16. Epub 2018 Jan 16.
    Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Ngan Shing Street, Shatin, NT, Hong Kong.
    Purpose: Despite numerous studies on the utility of GATA-3 as breast cancer marker, its comparison with other breast markers, its concordance between primary and metastatic tumors and its expression in primary cancers from sites with frequent breast metastases remains unclear.

    Methods: To address these questions, totally 993 invasive breast cancers (IBC), 254 paired nodal metastases, 23 distant metastases, and 208 lung carcinomas were included. GATA-3 expression was analyzed by immunohistochemistry and compared to other breast markers [gross cystic disease fluid protein 15 (GCDFP-15) and mammaglobin (MGB)]. Read More

    Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
    Breast Cancer Res Treat 2018 Jan 15. Epub 2018 Jan 15.
    Molecular Diagnostics Laboratory, INRaSTES, National Centre for Scientific Research 'Demokritos', Patriarchou Gregoriou E' & Neapoleos Street, 15310, Athens, Greece.
    Purpose: Male breast cancer (MBC) is a rare cancer entity, with mutations in BRCA1 and BRCA2 genes accounting for ~ 10% of patients. Multiple-gene sequencing has already entered clinical practice for female breast cancer, whereas the performance of panel testing in MBC has not been studied extensively. Therefore, the aim of this study was to evaluate the clinical utility of panel testing for MBC, by the largest gene panel used so far, through investigation of patients deriving from a population with known founder effects. Read More

    BRCA1 and BRCA2 germline variants in breast cancer patients from the Republic of Macedonia.
    Breast Cancer Res Treat 2018 Jan 15. Epub 2018 Jan 15.
    Research Centre for Genetic Engineering and Biotechnology "Georgi D. Efremov", Macedonian Academy of Sciences and Arts, Krste Misirkov 2, Skopje, Republic of Macedonia.
    Purpose: We aimed to establish the spectrum of BRCA1/2 mutations among the breast cancer (BC) patients from the Republic of Macedonia.

    Methods: We used targeted next-generation sequencing (NGS), Sanger DNA sequencing, and multiplex ligation probe amplification analysis (MLPA) to search for point mutations and deletions/duplications involving BRCA1 and BRCA2-coding regions.

    Results: We have analyzed a total of 313 BC patients, enriched for family history of cancer, early age of onset and bilateral and/or triple negative (TN) BC. Read More

    Breast conserving surgery in combination with intraoperative radiotherapy after previous external beam therapy: an option to avoid mastectomy.
    Breast Cancer Res Treat 2018 Jan 15. Epub 2018 Jan 15.
    Department of Radiation Oncology, Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany.
    Purpose: Mastectomy is the standard procedure in patients with in-breast tumor recurrence (IBTR) or breast cancer after irradiation of the chest due to Hodgkin's disease. In certain cases a second breast conserving surgery (BCS) in combination with intraoperative radiotherapy (IORT) is possible. To date, data concerning BCS in combination with IORT in pre-irradiated patients are limited. Read More

    Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.
    Breast Cancer Res Treat 2018 Jan 13. Epub 2018 Jan 13.
    Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.
    Purpose: Prior studies have identified shortcomings in the quality of care for early-stage breast cancer. Guidelines recommend systemic therapy for metastatic breast cancer (MBC), but few studies have examined guideline concordance for these patients.

    Methods: We used Surveillance, Epidemiology, and End Results (SEER)-Medicare data to identify patients aged ≥ 66 diagnosed in 2010-2011 with de novo MBC who were continuously enrolled in fee-for-service Medicare. Read More

    Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
    Breast Cancer Res Treat 2018 Jan 13. Epub 2018 Jan 13.
    Department of Breast Surgery, Fudan University Shanghai Cancer Center, 270 Dongan Road, Xuhui, 200032, Shanghai, People's Republic of China.
    Objective: To investigate ovarian function and therapeutic efficacy among estrogen receptor (ER)-positive, premenopausal breast cancer patients treated with gonadotropin-releasing hormone agonist (GnRHa) and chemotherapy simultaneously or sequentially.

    Method: This study was a phase 3, open-label, parallel, randomized controlled trial (NCT01712893). Two hundred sixteen premenopausal patients (under 45 years) diagnosed with invasive ER-positive breast cancer were enrolled from July 2009 to May 2013 and randomized at a 1:1 ratio to receive (neo)adjuvant chemotherapy combined with sequential or simultaneous GnRHa treatment. Read More

    Breast cancer survivorship: state of the science.
    Breast Cancer Res Treat 2018 Jan 13. Epub 2018 Jan 13.
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
    Purpose: Only recently has breast cancer survivorship earned formal recognition as a research discipline. Complicating survivorship research is the frequent overlap between aging and treatment sequelae. The ACS/ASCO 2016 Breast Cancer Survivorship Care Guideline (Guideline) reflects comprehensive literature review through April 2015, while the jointly sponsored, inaugural Cancer Survivorship Symposium in 2016 (Symposium) reflects ongoing research activity in the area. Read More

    Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study.
    Breast Cancer Res Treat 2018 Jan 12. Epub 2018 Jan 12.
    Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20251, Hamburg, Germany.
    Purpose: To identify modifiable factors predictive of long-term adherence to adjuvant endocrine therapy (AET).

    Methods: As part of a 2-year cohort study in primary care (n = 116), we investigated whether initial treatment expectations predict adherence at 24 months after controlling for demographic, medical, and psychosocial variables. Treatment expectations were measured as necessity-concern beliefs, expected side-effect severity, and expected coping with side effects. Read More

    Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer.
    Breast Cancer Res Treat 2018 Jan 12. Epub 2018 Jan 12.
    Translational Oncology Laboratory, Centro Regional de Investigaciones Biomédicas (CRIB), Universidad de Castilla La Mancha (UCLM), C/Almansa 14, 02008, Albacete, Spain.
    Purpose: Although obesity is a risk factor for breast cancer, little effort has been made in the identification of druggable molecular alterations in obese-breast cancer patients. Tumors are controlled by their surrounding microenvironment, in which the adipose tissue is a main component. In this work, we intended to describe molecular alterations at a transcriptomic and protein-protein interaction (PPI) level between obese and non-obese patients. Read More

    The impact of obesity on outcomes for patients undergoing mastectomy using the ACS-NSQIP data set.
    Breast Cancer Res Treat 2018 Jan 11. Epub 2018 Jan 11.
    Department of Surgical Oncology, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC, 27157, USA.
    Purpose: According to the World Health Organization (WHO), 34.7% of females in the United States are obese (BMI ≥ 30) in 2014, compared to 32.5% in 2010. Read More

    Correction to: Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes.
    Breast Cancer Res Treat 2018 Jan 11. Epub 2018 Jan 11.
    Department of Surgical Oncology, VU University Medical Center, De Boelelaan 1117, Room 7F-020, 1081 HV, Amsterdam, The Netherlands.
    In the original publication of the article, Table 2 was published incorrectly. The corrected Table 2 is given in this erratum. The original article has been corrected. Read More

    Correction to: Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors.
    Breast Cancer Res Treat 2018 Jan 11. Epub 2018 Jan 11.
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Rd NW, Washington, D.C., 20057, USA.
    In the original publication, the values provided for the isoflavone and glucosinolate intake variables were incorrectly labeled in Table 1. The correct values of 6.3 mg/day for isoflavone intake, and 20. Read More

    Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer.
    Breast Cancer Res Treat 2018 Jan 9. Epub 2018 Jan 9.
    Department of Oncology-Pathology, Karolinska University Hospital, Karolinska Institutet, Radiumhemmet, 171 76, Stockholm, Sweden.
    Purpose: To evaluate the sensitivity and specificity of different screening modalities in women with a family history of breast cancer.

    Methods: Our blinded, prospective, comparative cohort analysis included three types of screening, mammography, ultrasound, and clinical breast examination once per year for 6 years. Eligible patients for this study were healthy women with ≥ 17% lifetime risk of breast cancer or with a mutation in BRCA1 or BRCA2. Read More

    Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study.
    Breast Cancer Res Treat 2018 Jan 8. Epub 2018 Jan 8.
    Department of Pharmacy, National University of Singapore, Blk S4A Level 3, 18 Science Drive 4, Singapore, 117543, Singapore.
    Purpose: Cancer-related fatigue (CRF) and chemotherapy-related cognitive impairment (CRCI) are reported to be associated with mitochondrial dysfunction. Hence, mitochondrial DNA (mtDNA) content, a biomarker of mitochondrial dysfunction, is hypothesized to correlate with the onset of CRF and CRCI. This study aims to evaluate the association between peripheral blood mtDNA content reduction and severity of CRF and CRCI in patients receiving chemotherapy. Read More

    Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
    Breast Cancer Res Treat 2018 Jan 5. Epub 2018 Jan 5.
    Division of Cancer, Imperial College Faculty of Medicine, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK.
    In the original publication, Fig. 1 depicting the blot for EP300 in CAL51 cells (Fig. 1c) was unintentionally duplicated with that from MDA-MB-231 cells (Fig. Read More

    Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry.
    Breast Cancer Res Treat 2018 Jan 4. Epub 2018 Jan 4.
    Department of Public Health Sciences, University of Chicago, 5841 S. Maryland Ave, MC 2007, Chicago, IL, 60637, USA.
    Background: Few studies have evaluated the performance of existing breast cancer risk prediction models among women of African ancestry. In replication studies of genetic variants, a change in direction of the risk association is a common phenomenon. Termed flip-flop, it means that a variant is risk factor in one population but protective in another, affecting the performance of risk prediction models. Read More

    Observation versus excision of lobular neoplasia on core needle biopsy of the breast.
    Breast Cancer Res Treat 2018 Jan 3. Epub 2018 Jan 3.
    Dubin Breast Center of the Tisch Cancer Institute, New York, USA.
    Purpose: Controversy surrounds management of lobular neoplasia (LN), [atypical lobular hyperplasia (ALH) or lobular carcinoma in situ (LCIS)], diagnosed on core needle biopsy (CNB). Retrospective series of pure ALH and LCIS reported "upgrade" rate to DCIS or invasive cancer in 0-40%. Few reports document radiologic/pathologic correlation to exclude cases of discordance that are the likely source of most upgrades, and there is minimal data on outcomes with follow-up imaging and clinical surveillance. Read More

    High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Breast Cancer Res Treat 2018 Jan 2. Epub 2018 Jan 2.
    Department of Molecular Oncology, King Faisal Specialist Hospital and Research Center, PO Box: 3354, Riyadh, 11211, Saudi Arabia.
    Purpose: The BRCA1 and BRCA2 (BRCA) genes are heavily involved in mammalian cell DNA repair processes. Germline pathogenic mutations in BRCA increase the lifetime risk of developing breast and/or ovarian cancer in women. In the Arabian Peninsula, most breast and ovarian cancers are diagnosed as early-onset cases, some of which may be due to germline variants in BRCA genes. Read More

    Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.
    Breast Cancer Res Treat 2017 Dec 30. Epub 2017 Dec 30.
    Division of Medical Oncology, Mayo Clinic, 200 First Street S.W., Rochester, MN, 55905, USA.
    Purpose: In estrogen receptor-positive (ER+) breast cancer models, activation of Aurora A kinase (AURKA) is associated with downregulation of ERα expression and resistance to endocrine therapy. Alisertib is an oral selective inhibitor of AURKA. The primary objectives of this phase I trial were to determine the recommended phase II dose (RP2D) and evaluate the toxicities and clinical activity of alisertib combined with fulvestrant in patients with ER+ metastatic breast cancer (MBC). Read More

    Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
    Breast Cancer Res Treat 2017 Dec 27. Epub 2017 Dec 27.
    Breast Cancer Research Laboratory, Department of Medicine, Institut Jules Bordet and L'Université Libre de Bruxelles (U.L.B), Blvd de Waterloo 121, Brussels, Belgium.
    Background: Biomarkers of cardiac damages, such as troponin T (TnT) and the amino-terminal fragment of brain natriuretic peptide (NT-proBNP), may be useful as early predictors of cardiac dysfunction. The role of these biomarkers in patients receiving lapatinib and/or trastuzumab before anthracyclines is unknown. This study explores TnT and NT-proBNP as predictors of early cardiac toxicity in neoadjuvant breast cancer patients. Read More

    Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Breast Cancer Res Treat 2017 Dec 23. Epub 2017 Dec 23.
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, CC 2241, Stanford, CA, 94305-5826, USA.
    Purpose: Defects in the homologous recombination (HR) DNA repair pathway sensitize tumors to therapeutics that target this pathway. A significant proportion of triple-negative breast cancers (TNBC) carry HR defects. The HRD assay is highly associated with sensitivity to neoadjuvant platinum-based chemotherapy in TNBC. Read More

    Interventions are needed to support patient-provider decision-making for DCIS: a scoping review.
    Breast Cancer Res Treat 2017 Dec 23. Epub 2017 Dec 23.
    University Health Network, Toronto, Canada.
    Purpose: Prognostic and treatment uncertainty make ductal carcinoma in situ (DCIS) complex to manage. The purpose of this study was to describe research that evaluated DCIS communication experiences, needs and interventions among DCIS patients or physicians.

    Methods: MEDLINE, EMBASE, CINAHL and The Cochrane Library were searched from inception to February 2017. Read More

    Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma.
    Breast Cancer Res Treat 2017 Dec 22. Epub 2017 Dec 22.
    Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
    Purpose: Complex interactions occur between cancer cells and cells in the tumor microenvironment. In this study, the prognostic value of the interplay between tumor-stroma ratio (TSR) and the immune status of tumors in breast cancer patients was evaluated.

    Methods: A cohort of 574 breast cancer patients was analyzed. Read More

    Late breast cancer treatment-related symptoms and functioning: associations with physical activity adoption and maintenance during a lifestyle intervention for rural survivors.
    Breast Cancer Res Treat 2017 Dec 22. Epub 2017 Dec 22.
    Department of Preventive Medicine and Public Health, University of Kansas Medical Center, MS 1008, 3901 Rainbow Blvd, Kansas, KS, 66160, USA.
    Purpose: Physical activity may be difficult for survivors with poorer functioning following primary treatment. The study examined whether late symptoms of breast cancer treatment impact PA adoption (0-6 months) and maintenance (6-18 months) during a weight management intervention, and whether late symptoms influence PA when accounting for overall functioning.

    Methods: Secondary analyses were conducted using a sample of survivors participating in a weight management intervention and who provided valid weight and accelerometer data at baseline and 6 months (N = 176). Read More

    Comments on "Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors" by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017.
    Breast Cancer Res Treat 2017 Dec 21. Epub 2017 Dec 21.
    Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Perú.
    We would like to express our opinion regarding a Parise and Caggiano paper recently published in your journal. We certainly believe this is a great contribution, since it found that node-negative HER2 (+) breast cancer patients have better survival contrary to the common knowledge. This finding could reflect the consequences of targeted therapies that are changing the natural history of the disease. Read More

    Mammography use among women aged 18-39 years in the United States.
    Breast Cancer Res Treat 2017 Dec 20. Epub 2017 Dec 20.
    Reproductive Statistics Branch, Division of Vital Statistics, National Center for Health Statistics, CDC, Hyattsville, MD, USA.
    Purpose: Recommendations for breast cancer screening using mammography target asymptomatic women aged ≥ 40 years who are not at increased risk for breast cancer. Evidence is not available to demonstrate benefits of screening with mammography at younger ages, and little is known about mammography use among younger women. This study described mammography use among women aged 18-39 years. Read More

    Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis.
    Breast Cancer Res Treat 2017 Dec 20. Epub 2017 Dec 20.
    Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.
    Purpose: Evidence suggests anti-estrogen endocrine therapy (ET) is associated with adverse cognitive effects; however, findings are based on small samples and vary in the cognitive abilities affected. We conducted a meta-analysis to quantitatively synthesize the evidence.

    Methods: Electronic databases were searched in November 2016. Read More

    1 OF 167